<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318005</url>
  </required_header>
  <id_info>
    <org_study_id>HS-10-00455</org_study_id>
    <nct_id>NCT01318005</nct_id>
  </id_info>
  <brief_title>Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation</brief_title>
  <acronym>OCP2</acronym>
  <official_title>The Effects of Dose and Formulation of Oral Contraceptives (OCs) on Breast-Cell Proliferation: Can the Chemopreventive Effects of OCs on Endometrial and Ovarian Cancer be Extended to Breast Cancer?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to gain a better understanding of the changes that may
      occur in the breast when a woman uses an oral contraceptive (birth control pill). Some
      research indicates that women who use birth control pills with lower amounts of estrogen (a
      hormone in the birth control pill) may have lower breast cell growth than women who use birth
      control pills with a higher amount of estrogen; this research will examine that in detail.
      This research will also test whether the results found in HS-07-00269 can be confirmed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure breast cell proliferation levels between the three oral contraceptive dose groups.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Oral Contraceptive</condition>
  <arm_group>
    <arm_group_label>Ortho-Novum® 1/35</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ovcon® 35</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovcon® 35 is an oral contraceptive that contains less progestin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microgestin Fe® 1/20</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>is an oral contraceptive that contains less estrogen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive: Ortho-Novum® 1/35</intervention_name>
    <description>Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.</description>
    <arm_group_label>Ortho-Novum® 1/35</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive: Ovcon® 35</intervention_name>
    <description>Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.</description>
    <arm_group_label>Ovcon® 35</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive: Microgestin Fe® 1/20</intervention_name>
    <description>Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.</description>
    <arm_group_label>Microgestin Fe® 1/20</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-35

          2. BMI &lt;30 kg/m2

          3. Premenopausal with regular cycles or currently taking an OC

          4. Not currently or recently pregnant or nursing (within previous 6 months)

          5. Non-smoker

          6. No use of antibiotics within the prior 4 weeks

          7. Competent to provide written informed consent (as judged by study team)

          8. Willing to adhere to the OC regimen

          9. Willingness to refrain from the use of aspirin or NSAIDS 10 days pior to the biopsy
             appointment and one week following the biopsy procedure

         10. Willing and able to refrain from use of fish oils 10 days prior to the biopsy
             appointment and one week following the biopsy procedure

        Exclusion Criteria:

          1. Diabetes

          2. Abnormal breast examination

          3. Abnormal PT/INR and/or CBC with platelets test results (as determined by one of the
             study physicians)

          4. History or current therapeutic or prophylactic use of anticoagulants

          5. Known bleeding disorder or history of unexplained bleeding or bruising

          6. History of breast cancer or previous diagnostic breast biopsy

          7. Known allergy to local anesthetic
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather MacDonald, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna H Wu, Ph.D.</last_name>
    <phone>323 865 0484</phone>
    <email>annawu@usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leticia Vasquez-Caldera, B.A.</last_name>
    <phone>323 865 0407</phone>
    <email>vasquezc@usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USC University Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Heather MacDonald, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norinyl</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Mestranol</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

